---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035830"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:39:27.342343+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical Q2 net sales $25.8M (+43% YoY), net income $0.3M, raises FY 2024 guidance

## Summary
- Net sales $25.8M (+43% YoY); gross profit $4.6M (+341%); gross margin expanded to 18% from 6%.
- Net income $0.3M vs net loss of $3.3M in Q2 2023; adjusted EBITDA $1.5M vs negative $2.3M.
- Generated $1.4M in cash flow from operations; cash and equivalents rose to $11.9M from $8.6M.
- FY 2024 net product sales guidance raised to $95M–$98M (from $90M–$94M) and Adjusted EBITDA to $0.75M–$1.5M.
- Promoted Tim Chole to Chief Commercial Officer; amended Evoqua asset purchase agreement for extended payment terms.

## SEC filing metadata
- accession: 0001628280-24-035830
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000162828024035830/0001628280-24-035830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000162828024035830/rmti-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035830
- JSON: https://secwatch.observer/filing/0001628280-24-035830.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.